Bravelle

Bravelle

A lyophilised formulation of follicle-stimulating hormone purified from the urine of postmenopausal women, which is used to induce ovulation and as part of the regimen for assisted reproductive technologies—e.g., in vitro fertilisation.

Contraindications Bravelle
• High FSH level indicating primary ovarian failure;
• Uncontrolled thyroid and adrenal dysfunction;
• An organic intracranial lesion—especially pituitary tumours;
• Any cause of infertility other than anovulation;
• Abnormal bleeding of undetermined origin;
• Ovarian cysts or enlargement not due to polycystic ovary syndrome;
• Prior hypersensitivity to urofollitropins, purified;
• Pregnancy.
Mentioned in ?
References in periodicals archive ?
The FDA permitted for MENOPUR and BRAVELLE mixed and administered in a single injection and it sanctioning was also based on pharmacodynamics study, that evaluated safety and stability of the treatment.
CHAPTER 5 METHODS OF TREATMENT 63 FERTILITY PHARMACEUTICALS 63 INTRODUCTION AND TYPES 63 Antagon 64 Bravelle 65 Cetrotide 65 Clomid 65 Crinone and Prometrium 66 Fertinex 67 Follistim 67 Gonal-F 67 Humegon 68 Lupron 68 Novarel 68 Ovidrel 69 Parlodel 69 Pregnyl 69 Profasi 69 Prometrium 69 Repronex 69 Serophene 70 TABLE 8 SELECTED PRESCRIPTION FERTILITY DRUGS 70 MARKET REVENUES AND FORECAST 71 TABLE 9 MARKET SIZE OF GLOBAL INFERTILITY PHARMACEUTICALS AT U.
The label update comes as an output of the COMBINE trial which revealed that MENOPUR as well as BRAVELLE can be safely mixed and administered in a single injection.
The Company markets BRAVELLE, MENOPUR, REPRONEX[R] (menotropins for injection, USP), NOVAREL and ENDOMETRIN in the U.
The label update is a result of the COMBINE trial which demonstrated that both MENOPUR and BRAVELLE can be safely mixed and administered in a single injection.
Contractor address : ZA de la Bravelle, 945 rue du Faubourg d~Esquerchin
including BRAVELLE (urofollitropin for injection, purified), MENOPUR (menotropins for injection, USP) and ENDOMETRIN (progesterone) Vaginal Insert, 100 mg, and LYSTEDA (TM)(tranexamic acid) tablets.
She used MENOPUR and BRAVELLE which resulted in more than 20 healthy, viable eggs.
They include: BRAVELLE (urofollitropin for injection, purified), MENOPUR (menotropins for injection, USP) and REPRONEX (menotropins for injection, USP), NOVAREL (chorionic gonadotropin for injection, USP), ENDOMETRIN (progesterone) Vaginal Insert, LYSTEDA (tranexamic acid tablets), FIRMAGON (degarelix for injection), and EUFLEXXA (1% sodium hyaluronate).
They include: BRAVELLE (urofollitropin for injection, purified), MENOPUR and REPRONEX (menotropins for injection, USP), Novarel (chorionic gonadotropin for injection, USP), ENDOMETRIN (progesterone) Vaginal Insert, LYSTEDA(TM) (tranexamic acid tablets), FIRMAGON (degarelix for injection), PROSED DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA (1% sodium hyaluronate).
They include: BRAVELLE (urofollitropin for injection, purified), MENOPUR (menotropins for injection, USP) and REPRONEX (menotropins for injection, USP), Novarel (chorionic gonadotropin for injection, USP), ENDOMETRIN (progesterone) Vaginal Insert, 100 mg, LYSTEDA(TM) (tranexamic acid tablets), FIRMAGON (degarelix for injection), PROSED DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), and EUFLEXXA (1 percent sodium hyaluronate).
They include: LYSTEDA tablets, BRAVELLE (urofollitropin for injection, purified), MENOPUR (menotropins for injection, USP) and REPRONEX (menotropins for injection, USP), NOVAREL (chorionic gonadotropin for injection, USP), ENDOMETRIN (progesterone) Vaginal Insert, 100 mg, FIRMAGON (degarelix for injection), PROSED DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA (1% sodium hyaluronate).